Live Marvell Technology Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow Adaptive Biotechnologies Corp

Get SEC filing alerts via email and in your feed for Adaptive Biotechnologies Corp

ADPT

Adaptive Biotechnologies Corp

About Adaptive Biotechnologies Corp

Adaptive Biotechnologies Corporation develops immune medicine products leveraging proprietary next-generation sequencing and machine learning to decode the adaptive immune system. Its core offerings include clonoSEQ, an FDA-authorized assay for detecting minimal residual disease (MRD) in lymphoid cancers, serving clinicians and biopharmaceutical partners. The company also advances immune-based therapies for cancer and autoimmune diseases through its extensive immunosequencing platform, large clinical database, and collaborations with pharmaceutical firms.
This description was generated via AI from an annual report. Updated 8 months ago.

Latest SEC Filings from Adaptive Biotechnologies Corp

1
1
Adaptive Biotechnologies Corp Adaptive Biotechnologies Reports 35% Revenue Growth to $70.9 Million in Q1 2026

Via official filing (AI summary) | about 1 month ago | 0 comments

2
1
Adaptive Biotechnologies Corp Adaptive Biotechnologies Reports 2025 Revenue Growth to $277M, Driven by MRD Business

Via official filing (AI summary) | 3 months ago | 0 comments

3
1
Adaptive Biotechnologies Corp Adaptive Biotechnologies Reports 102% Revenue Growth to $93.973 Million in Q3 2025

Via official filing (AI summary) | 7 months ago | 0 comments

4
1
Adaptive Biotechnologies Corp Adaptive Biotechnologies Reports 36% Revenue Growth to $58.9 Million in Q2 2025

Via official filing (AI summary) | 10 months ago | 0 comments

5
1
Adaptive Biotechnologies Corp Adaptive Biotechnologies Reports $52.4M Revenue in Q1 2025, Driven by MRD Growth

Via official filing (AI summary) | about 1 year ago | 0 comments

6
1
Adaptive Biotechnologies Corp Adaptive Biotechnologies Reports $179M Revenue in 2024, Driven by MRD Business Growth

Via official filing (AI summary) | about 1 year ago | 0 comments

7
1
Adaptive Biotechnologies Corp Adaptive Biotechnologies Reports 22% Revenue Growth, Narrower Net Loss in Q3 2024

Via official filing (AI summary) | over 1 year ago | 0 comments